Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
130
-
Total 13F shares, excl. options
-
98.5M
-
Shares change
-
-2.95M
-
Total reported value, excl. options
-
$333M
-
Value change
-
-$7.6M
-
Put/Call ratio
-
2.01
-
Number of buys
-
61
-
Number of sells
-
-55
-
Price
-
$3.38
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q1 2021
161 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q1 2021.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 130 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 98.5M shares
of 236M outstanding shares and own 41.71% of the company stock.
Largest 10 shareholders include STATE STREET CORP (17M shares), BlackRock Inc. (12.4M shares), VANGUARD GROUP INC (11.7M shares), WELLINGTON MANAGEMENT GROUP LLP (10.8M shares), Nantahala Capital Management, LLC (5.15M shares), SATTER MANAGEMENT CO., L.P. (4.65M shares), MORGAN STANLEY (3.34M shares), GOLDMAN SACHS GROUP INC (2.78M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2.67M shares), and GEODE CAPITAL MANAGEMENT, LLC (2.6M shares).
This table shows the top 130 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.